Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Nurix Therapeutics (NRIX), a clinical stage biopharmaceutical company focused on developing targeted protein modulation drugs for cancer and inflammatory diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's president and CEO, Arthur T. Sands, M.D., Ph.D., will deliver a corporate update presentation on Monday, January 13, 2025, at 3:00 p.m. PT in San Francisco.
The presentation will be accessible through a live webcast, with a link available in the Investors section of the Nurix website. For those unable to attend live, the webcast recording will remain accessible for 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – NRIX
On the day this news was published, NRIX declined 2.49%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:00 p.m. PT, in San Francisco.
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types, including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FAQ
When is Nurix Therapeutics (NRIX) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will the NRIX J.P. Morgan Healthcare Conference webcast be available?
What therapeutic areas does Nurix Therapeutics (NRIX) focus on?
Where can investors access the NRIX J.P. Morgan Healthcare Conference presentation webcast?
